|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Esmolol#Clinical Studies]] |
| {{Esmolol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Clinical Studies==
| |
| | |
| ===Supraventricular Tachycardia===
| |
| | |
| In two multicenter, randomized, double-blind, controlled comparisons of BREVIBLOC injection with placebo and [[propranolol]], maintenance doses of 50 to 300 mcg/kg/min of BREVIBLOC were found to be more effective than placebo and about as effective as [[propranolol]], 3-6 mg given by bolus injections, in the treatment of [[supraventricular tachycardia]], principally [[atrial fibrillation]] and [[atrial flutter]]. The majority of these patients developed their [[arrhythmias]] postoperatively. About 60-70% of the patients treated with BREVIBLOC developed either a 20% reduction in heart rate, a decrease in heart rate to less than 100 bpm, or, rarely, conversion to normal sinus rhythm and about 95% of these patients did so at a dosage of 200 mcg/kg/min or less. The average effective dosage of BREVIBLOC was approximately 100 mcg/kg/min in the two studies. Other multicenter baseline-controlled studies gave similar results. In the comparison with [[propranolol]], about 50% of patients in both the BREVIBLOC and [[propranolol]] groups were on concomitant [[digoxin]]. Response rates were slightly higher with both [[beta blocker]]s in the digoxin-treated patients.
| |
| | |
| In all studies significant decreases of blood pressure occurred in 20-50% of patients, identified either as adverse reaction reports by investigators, or by observation of systolic pressure less than 90 mmHg or diastolic pressure less than 50 mmHg. The [[hypotension]] was symptomatic (mainly [[hyperhidrosis]] or [[dizziness]]) in about 12% of patients, and therapy was discontinued in about 11% of patients, about half of whom were symptomatic. Hypotension was more common with BREVIBLOC (53%) than with [[propranolol]] (17%). The hypotension was rapidly reversible with decreased infusion rate or after discontinuation of therapy with BREVIBLOC. For both BREVIBLOC and propranolol, hypotension was reported less frequently in patients receiving concomitant digoxin.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BREVIBLOC (ESMOLOL HYDROCHLORIDE) INJECTION [BAXTER HEALTHCARE CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
|
| |
|
| | [[Category:Beta blockers]] |
| | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |